StreetInsider.com News Articles

NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 09:00:00 -0400

Company presentation on Tuesday, September 15 at 4:30 p.m. ET
Management will be available for one-on-one investor meetings during the conference

CAMBRIDGE, Mass., Sept. 10, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that management will participate in the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, in New York City.

NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 09:00:00 -0400

Company presentation on Tuesday, September 15 at 4:30 p.m. ET
Management will be available for one-on-one investor meetings during the conference

H.C. Wainwright Starts NeuroSense Therapeutics Ltd. (NRSN) at Buy

Thu, 03 Sep 2026 06:03:10 -0400

H.C. Wainwright initiates coverage on NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) with a Buy rating and a price target of $8.00.

For an analyst ratings summary and ratings history on NeuroSense Therapeutics Ltd. click here. For more ratings news on NeuroSense Therapeutics Ltd. click here.

Shares of NeuroSense Therapeutics Ltd. closed at $0.41 yesterday.

Form 6-K NeuroSense Therapeutics For: Aug 27

Thu, 27 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260827/26990098.html

Form 6-K NeuroSense Therapeutics For: Aug 27

Thu, 27 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260827/26990098.html

Form 6-K NeuroSense Therapeutics For: Aug 13

Thu, 13 Aug 2026 10:56:00 -0400

si-local-file:///var/storage/secattach/20260813/26918357.html

Form 6-K NeuroSense Therapeutics For: Aug 13

Thu, 13 Aug 2026 10:56:00 -0400

si-local-file:///var/storage/secattach/20260813/26918357.html

NeuroSense faces funding delays for Phase 3 ALS trial, Nasdaq issues

Thu, 13 Aug 2026 09:31:20 -0400

NeuroSense Therapeutics (NASDAQ: NRSN) disclosed in a shareholder letter that securing financing for its Phase 3 PARAGON study of PrimeC in amyotrophic lateral sclerosis (ALS) has taken longer than anticipated, while the company also faces Nasdaq listing deficiencies.

The FDA has cleared NeuroSense to initiate PARAGON, which is expected to enroll approximately 300 participants, primarily in the United States. The company said it is pursuing financing through discussions with pharmaceutical companies, strategic partners, investors, grants, and other non-dilutive funding sources.

In April 2026, CEO Alon Ben-Noon and CFO Or Eisenberg each invested $200,000 in the company. Combined with a contribution from an

NeuroSense faces funding delays for Phase 3 ALS trial, Nasdaq issues

Thu, 13 Aug 2026 09:31:20 -0400

In April 2026, CEO Alon Ben-Noon and CFO Or Eisenberg each invested $200,000 in the company. Combined with a contribution from an

NeuroSense faces funding delays for Phase 3 ALS trial, Nasdaq issues

Thu, 13 Aug 2026 09:31:20 -0400

In April 2026, CEO Alon Ben-Noon and CFO Or Eisenberg each invested $200,000 in the company. Combined with a contribution from an

NeuroSense faces funding delays for Phase 3 ALS trial, Nasdaq issues

Thu, 13 Aug 2026 09:31:20 -0400

In April 2026, CEO Alon Ben-Noon and CFO Or Eisenberg each invested $200,000 in the company. Combined with a contribution from an

NeuroSense faces funding delays for Phase 3 ALS trial, Nasdaq issues

Thu, 13 Aug 2026 09:31:20 -0400

In April 2026, CEO Alon Ben-Noon and CFO Or Eisenberg each invested $200,000 in the company. Combined with a contribution from an

NeuroSense faces funding delays for Phase 3 ALS trial, Nasdaq issues

Thu, 13 Aug 2026 09:31:20 -0400

In April 2026, CEO Alon Ben-Noon and CFO Or Eisenberg each invested $200,000 in the company. Combined with a contribution from an

NeuroSense Issues CEO Letter to Shareholders